Lahore - Shaikh Zayed Hospital Lahore marked World Arthritis Day with an awareness walk and a mini educational session organized by the Department of ...

Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as its top picks in the emerging technology sector. For Nektar, the firm cited the novel Treg mechanism used in its phase 3 asset ...

ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...

Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet ...

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...

Johnson & Johnson’s 44% one-year gain has pushed its valuation higher, but expanding growth drivers across pharmaceuticals ...

On Nov. 3, California voters will be confronted with 14 propositions. Together, they are quite challenging, because several ...

From Cardiac Immunology to Translational Advances in Cardio-Oncology / Anthracycline Cardiotoxicity, atherosclerosis, body ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitis—upside vs.

Humira, the drug that built AbbVie (NYSE:ABBV), sold $756 million last quarter, down 35.9%. And yet total revenue still ...